[Haloperidol. Plasma monitoring and hormonal effects of treatment].
Therapeutic plasma monitoring of haloperidol, a major neuroleptic, measured by radioimmunoassay, has shown a rather good correlation between plasma level and dosage but with large interindividual variation in children as in adults; age seems not to have any effect on haloperidol metabolism. 80% of subjects present a concomitant prolactin levels variation, whereas in 20% no prolactin response is found. During acute kinetics of either a 10 mg oral haloperidol administration or a 250 mg intramuscular haloperidol decanoate injection, a parallel elevation of prolactin, cortisol, immunoreactive bêta-endorphin and bêta-lipotropin plasma levels occur, at the same time as haloperidol plasma levels. Those rise with a good equivalence between the two doses of the two forms.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004723:Endorphins / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006220:Haloperidol / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007273:Injections, Intramuscular; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D011388:Prolactin / Q000097:blood; D011618:Psychotic Disorders / Q000188:drug therapy; D011863:Radioimmunoassay; D013342:Stuttering / Q000097:blood / Q000188:drug therapy; D013981:Tic Disorders / Q000097:blood / Q000188:drug therapy; D013997:Time Factors; D001615:beta-Endorphin
D003692:Delayed-Action Preparations; D004723:Endorphins; D010908:Pituitary Hormones, Anterior; D001615:beta-Endorphin; D011388:Prolactin; D013006:Growth Hormone; D006220:Haloperidol; D006854:Hydrocortisone
Halopéridol. Surveillance plasmatique et incidence hormonale du traitement.